Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch

Paratek caps 20-year R&D journey with FDA OK for its broad spectrum antibiotic — time to talk launch

Source: 
Endpoints
snippet: 

Paratek has bagged its first — and second — FDA OK for its antibiotics on the same day.

The big approval, 20 years in the making, goes to omadacycline — dubbed Nuzyra — for both community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).